Senolytic treatment for low back pain
Matthew Mannarino, Hosni Cherif, Saber Ghazizadeh Darband, Oliver Wu Martinez, Kai Sheng, Elsa Cousineau, Seunghwan Lee, Magali Millecamps, Chan Gao, A. Gilbert, Cédric Peirs, Reza Sharif‐Naeini, Jean Ouellet, Laura S. Stone, Lisbet Haglund
Abstract
Senescent cells (SnCs) accumulate because of aging and external cellular stress throughout the body. They adopt a senescence-associated secretory phenotype (SASP) and release inflammatory and degenerative factors that actively contribute to age-related diseases, such as low back pain (LBP). The senolytics, o -vanillin and RG-7112, remove SnCs in human intervertebral discs (IVDs) and reduce SASP release, but it is unknown whether they can treat LBP. sparc −/− mice, with LBP, were treated orally with o -vanillin and RG-7112 as single or combination treatments. Treatment reduced LBP and SASP factor release and removed SnCs from the IVD and spinal cord. Treatment also lowered degeneration scores in the IVDs, improved vertebral bone quality, and reduced the expression of pain markers in the spinal cord. Together, our data suggest RG-7112 and o -vanillin as potential disease-modifying drugs for LBP and other painful disorders linked to cell senescence.